Here are five key points:
1. Xtant Medical’s shares closed at $3.29 on Oct. 23.
2. Brean Capital analyst Jason Wittes said Xtant Medical should grow pro-forma revenues at 12 percent.
3. The company currently has an analyst consensus of “hold.”
4. Xtant Medical had a quarterly revenue of $9.89 million, based on its June 30 report.
5. The company manufactures products for spine, orthopedic and joint surgeries.
More articles on devices:
China spinal fusion market to see double digit growth — 6 points
HSS conducts studies on a new modular partial wrist replacement: 5 takeaways
Wire stimulator technology provides chronic pain relief for San Antonio patients: 4 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
